AFTER MEGA SUCCESSFUL CONTINUOUS BUY CALLS FROM 205 AS PREDICTED IN 2 STOCK WILL HIT 300 BY YEAR END AUROBINDHO PAHRMA CROSSED 300 TOO
AT LAST YSTD FOR FIRST TIME YSTD WE GAVE SELL CAL TO OUR PAID CLINETS
SELL AUROPHARMA 305-307 SL 312 TGT 290-280 LOT SIZE 2000
TODAY STOCK IS FALLING AS WE PREDICTED HIT 299.50 LOW TODAY ALREADY MADE 12000 PROFIT IN BTST
STOCK FALL ON THE EFFECT OF THIS NEWS
AstraZeneca
Inc has sued Aurobindo Pharma Ltd and its US-based subsidiary, for
allegedly violating several patents of blockbuster heartburn drug
Nexium.
Nexium–generic esomeprazole magnesium delayed-release
tablets in 20 mg and 40 mg strengths–is a proton pump inhibitor which
reduces acid secretion, reducing the likelihood of developing ulcers. It
is prescribed for relief from acid reflux and to treat erosive
esophagitis. The drug clocks around $5 bln in annual sales and is
amongst the three top selling drugs globally.
